Business Description
bioAffinity Technologies Inc
NAICS : 541380
SIC : 2835
ISIN : US09076W3079
Total Employee Number:
57Description
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.24 | |||||
Equity-to-Asset | 0.46 | |||||
Debt-to-Equity | 0.38 | |||||
Debt-to-EBITDA | -0.09 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -17.72 | |||||
Beneish M-Score | -3.2 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 375.6 | |||||
3-Year EBITDA Growth Rate | 39.4 | |||||
3-Year EPS without NRI Growth Rate | 51.3 | |||||
3-Year FCF Growth Rate | 42.4 | |||||
3-Year Book Growth Rate | -65.6 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 21.6 | |||||
9-Day RSI | 23.42 | |||||
14-Day RSI | 26.55 | |||||
3-1 Month Momentum % | -54.63 | |||||
6-1 Month Momentum % | 14.29 | |||||
12-1 Month Momentum % | -83.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.36 | |||||
Quick Ratio | 1.34 | |||||
Cash Ratio | 0.97 | |||||
Days Inventory | 4.82 | |||||
Days Sales Outstanding | 38.27 | |||||
Days Payable | 98.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -152.6 | |||||
Shareholder Yield % | 10.42 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 32.45 | |||||
Operating Margin % | -207.22 | |||||
Net Margin % | -283.27 | |||||
EBITDA Margin % | -273.56 | |||||
FCF Margin % | -194.97 | |||||
OCF Margin % | -194.68 | |||||
ROE % | -414.75 | |||||
ROA % | -194.85 | |||||
ROIC % | -238.43 | |||||
3-Year ROIIC % | -153.18 | |||||
ROC (Joel Greenblatt) % | -1328.48 | |||||
ROCE % | -300.44 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.21 | |||||
PB Ratio | 0.95 | |||||
Price-to-Tangible-Book | 2.17 | |||||
EV-to-EBIT | -0.2 | |||||
EV-to-EBITDA | -0.2 | |||||
EV-to-Revenue | 0.55 | |||||
EV-to-FCF | -0.28 | |||||
Price-to-GF-Value | 0.18 | |||||
| Price-to-Net-Current-Asset-Value | 75.99 | |||||
Earnings Yield (Greenblatt) % | -500 | |||||
FCF Yield % | -227 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BIAF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
bioAffinity Technologies Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5.606 | ||
| EPS (TTM) ($) | -11.347 | ||
| Beta | -2.923 | ||
| 3-Year Sharpe Ratio | -0.18 | ||
| 3-Year Sortino Ratio | -0.4 | ||
| Volatility % | 294.87 | ||
| 14-Day RSI | 26.55 | ||
| 14-Day ATR ($) | 0.106979 | ||
| 20-Day SMA ($) | 0.92611 | ||
| 12-1 Month Momentum % | -83.66 | ||
| 52-Week Range ($) | 0.693 - 13.5 | ||
| Shares Outstanding (Mil) | 6.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
bioAffinity Technologies Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
bioAffinity Technologies Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 125 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 34 days | ||
| Guidance call for 2024 | 2026-06-24 10:00 | 0.84 (+5.40%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 2.12 (+9.28%) | ||
| General meeting for 2026 | 2026-04-30 08:00 | 2.43 (-7.25%) | ||
| Annual report for 2025 | 2026-03-16 | 2.12 (+18.11%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-13 | 1.07 (-2.73%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 1.88 (-10.90%) | ||
| 0.0333333:1 Stock Split | 2025-09-19 | 5.07 (-9.04%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 8.40 (+0.00%) |
Show
Entries
bioAffinity Technologies Inc Frequently Asked Questions
What is bioAffinity Technologies Inc(BIAF)'s stock price today?
The current price of BIAF is $0.76. The 52 week high of BIAF is $13.50 and 52 week low is $0.69.
When is next earnings date of bioAffinity Technologies Inc(BIAF)?
The next earnings date of bioAffinity Technologies Inc(BIAF) is 2026-08-14 Est..
Does bioAffinity Technologies Inc(BIAF) pay dividends? If so, how much?
bioAffinity Technologies Inc(BIAF) does not pay dividend.
Guru Commentaries on NAS:BIAF
No articles.
Press Release
Articles on bioAffinity Technologies Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers